ReviewOncogene2010
MicroRNA dysregulation in gastric cancer: a new player enters the game.
Review in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 2 syntheses or guidelines pooled it, 283 citations in OpenAlex.
- The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis.Clinical and experimental medicine · 2014Pooled it
- Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis.Digestive diseases and sciences · 2014Pooled it
- Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer.PloS one · 2013Trial
- Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors.Molecular oncology · 2025Review
- Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors.Biomedicines · 2024Review
- Uncovering the ceRNA Network Related to the Prognosis of Stomach Adenocarcinoma Among 898 Patient Samples.Biochemical genetics · 2024Article
- Implications of miRNAs dysregulation in amyotrophic lateral sclerosis: Challenging for clinical applications.Frontiers in neuroscience · 2023Review
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- MiRNA: Biological Regulator in Host-Parasite Interaction during Malaria Infection.International journal of environmental research and public health · 2022Review
- Micro-RNA Implications in Type-1 Diabetes Mellitus: A Review of Literature.International journal of molecular sciences · 2021Review
- Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer.World journal of surgical oncology · 2021Article
- MiR-873-5p targets THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance.Journal of gastrointestinal oncology · 2021Article
- miR-488-5p promotes esophageal squamous cell carcinoma progression by suppressing the P53 pathway.Journal of thoracic disease · 2021Article
- Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review).Oncology reports · 2021Review
- Long non-coding RNA LINC00887 promotes progression of lung carcinoma by targeting the microRNA-206/NRP1 axis.Oncology letters · 2021Article
- Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1.Molecular cancer · 2021Article
- MicroRNA-653-5p Promotes Gastric Cancer Proliferation and Metastasis by Targeting the SOCS6-STAT3 Pathway.Frontiers in molecular biosciences · 2021Article
- Role of Exosomal Non-coding RNAs in Gastric Cancer: Biological Functions and Potential Clinical Applications.Frontiers in oncology · 2021Review
- Non-coding RNAs underlying chemoresistance in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein-coding proto-oncogenes and tumor-suppressor genes. Recent discoveries have shed new light on the involvement of a class of noncoding RNA known as microRNA (miRNA) in gastric cancer. A substantial number of miRNAs show differential expression in gastric cancer tissues. Genes coding for these miRNAs have been characterized as novel proto-oncogenes and tumor-suppressor genes based on findings that these miRNAs control malignant phenotypes of gastric cancer cells. In this connection, miRNA dysregulation promotes cell-cycle progression, confers resistance to apoptosis, and enhances invasiveness and metastasis. Moreover, certain polymorphisms in miRNA genes are associated with increased risks for atrophic gastritis and gastric cancer, whereas circulating levels of miRNAs may serve as biomarkers for early diagnosis. Several miRNAs have also been shown to correlate with gastric cancer progression, and thus may be used as prognostic markers. Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of gastric cancer and promote the development of miRNA-directed therapeutics against this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.